Immuneering Corporation (IMRX), a clinical-stage oncology company, Thursday said it has signed a clinical supply agreement with ...

CAMBRIDGE, Mass. - Immuneering Corporation (NASDAQ:IMRX), a clinical-stage oncology company with a market capitalization of $59.31 million, has entered into a clinical supply agreement with Regeneron ...

Regeneron hosted a celebration to recognize the achievements of the 17 students selected as the Westchester 2025 Regeneron Science Talent Search Scholars. Beginning in 1942, the contest […] ...

Immuneering plans to evaluate IMM-1-104 in combination with Libtayo in patients with advanced non-small cell lung cancer in its ongoing Phase ...

Q4 2024 Earnings Call Transcript February 4, 2025 Operator: Hello, and welcome to Regeneron Pharmaceuticals Fourth Quarter 2024 Earnings Conference Call. My name is Tawanda, and I will be your ...

And that’s especially true when it comes to living room colour schemes. Most living room ideas need to keep up with the multifunctional nature and use of the living space, serving as a place for ...

If you're looking for a space where you can meet as a group, your library has meeting rooms for hire. At some libraries, you can hire a bank of computers and in others there are separate IT suites for ...

Trevogrumab is under clinical development by Regeneron Pharmaceuticals and currently in Phase II for Obesity. According to GlobalData, Phase II drugs for Obesity have a 29% phase transition success ...

More's the pity – we love the idea of decamping to our dedicated listening room and kicking back for a good couple of hours. The closest we get is playing tunes on the Sonos while vacuuming the house.

With a market cap of $77.3 billion, Regeneron Pharmaceuticals, Inc. (REGN) is a leading biotechnology company dedicated to discovering, developing, and commercializing innovative treatments for a ...

The event is scheduled to take place from January 20-24. Forum organizers say a record of around 900 business leaders, including from important emerging markets, will take part in the annual meeting ...